Education
About Us
Working with TipRanks
Follow Us
SAGE Therapeutics, Inc. (US) (SAGE)
:SAGE
SAGE Stock Chart & Stats
$8.68
-$0.02(-0.23%)
―
--
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SAGE Therapeutics News
SAGE FAQ
What was SAGE Therapeutics, Inc. (US)’s price range in the past 12 months?
Currently, no data Available
What is SAGE Therapeutics, Inc. (US)’s market cap?
Currently, no data Available
When is SAGE Therapeutics, Inc. (US)’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were SAGE Therapeutics, Inc. (US)’s earnings last quarter?
Currently, no data Available
Is SAGE Therapeutics, Inc. (US) overvalued?
According to Wall Street analysts SAGE Therapeutics, Inc. (US)’s price is currently Undervalued.
Does SAGE Therapeutics, Inc. (US) pay dividends?
SAGE Therapeutics, Inc. (US) does not currently pay dividends.
What is SAGE Therapeutics, Inc. (US)’s EPS estimate?
SAGE Therapeutics, Inc. (US)’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SAGE Therapeutics, Inc. (US) have?
Currently, no data Available
What happened to SAGE Therapeutics, Inc. (US)’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of SAGE Therapeutics, Inc. (US)?
Currently, no hedge funds are holding shares in SAGE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SAGE Therapeutics, Inc. (US)
SAGE Therapeutics (SAGE) is a biopharmaceutical company committed to developing novel therapies for central nervous system (CNS) disorders. Founded in 2010 and headquartered in Cambridge, Massachusetts, SAGE focuses on identifying and developing medicines that target the brain's neurotransmitter pathways to address conditions such as depression, insomnia, and other CNS-related diseases. The company's flagship products include Zulresso (brexanolone) for the treatment of postpartum depression and other promising compounds in its pipeline aimed at various psychiatric and neurological conditions.
Ownership Overview
―
Insiders
0.93%
Mutual Funds
― Other Institutional Investors
99.07% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---